HitGen Inc.

Overview

HitGen Inc. (SSE: 688222.SH) is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK, and Houston, USA. Its business centers on DNA-encoded library (DEL) technology, which it has extended into fragment-based drug discovery (FBDD), structure-based drug design (SBDD) and related platforms.

Services

• DEL design, synthesis and screening, including OpenDEL small-molecule libraries and DEL applications across targets such as PPIs, kinases, GPCRs, RNA and protein degraders.
• FBDD/SBDD drug discovery support.
• Medicinal, synthetic, peptide, process and analytical chemistry, plus high-throughput and computational chemistry.
• Biology services including protein science, NGS and bioinformatics, cell biology, pre-clinical studies and bioanalysis.
• Oligonucleotide services covering sequence design, monomer and solid support chemistry, oligonucleotide chemistry, nucleic acid delivery and CDMO.
• Protein degradation work covering E3 ligase binders, molecular glue degraders, PROTAC discovery and degrader evaluation.

Business model

HitGen states that it works through technical services, project out-licensing and product sales. It reports more than 600 clients worldwide, including pharmaceutical and biotechnology companies, chemical firms, foundations and research institutions. The company also advances its own internal programmes at clinical and preclinical stages.

Therapeutic focus areas

The website lists application areas in oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious diseases, metabolic diseases and cardiovascular diseases.